<!DOCTYPE html>
<html  lang="en" dir="ltr" prefix="og: https://ogp.me/ns#">
  <head>
    <meta charset="utf-8" />
<script async src="https://www.googletagmanager.com/gtag/js?id=G-273DTKB5QW"></script>
<meta name="description" content="Drug Trials Snapshots: LEQEMBI" />
<meta name="dcterms.title" content="Drug Trials Snapshots: LEQEMBI" />
<meta name="dcterms.creator" content="Center for Drug Evaluation and Research" />
<meta name="dcterms.description" content="Drug Trials Snapshots: LEQEMBI" />
<meta name="dcterms.publisher" content="FDA" />
<meta name="dcterms.type" content="Article" />
<meta name="dcterms.source" content="FDA" />
<meta property="og:site_name" content="U.S. Food and Drug Administration" />
<meta property="og:type" content="Article" />
<meta property="og:url" content="https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-leqembi" />
<meta property="og:title" content="Drug Trials Snapshots: LEQEMBI" />
<meta property="og:description" content="Drug Trials Snapshots: LEQEMBI" />
<meta property="og:updated_time" content="Tue, 10/08/2024 - 00:00" />
<meta property="article:publisher" content="FDA" />
<meta property="article:published_time" content="Wed, 04/29/2026 - 07:52" />
<meta property="article:modified_time" content="Tue, 10/08/2024 - 00:00" />
<meta name="google-site-verification" content="tWxlDhm4ANdksJZPj7TBmHgNoMqZCnecPp0Aa2vC9XA" />
<meta name="twitter:card" content="summary_large_image" />
<meta name="twitter:site" content="@US_FDA" />
<meta property="twitter:description" content="Drug Trials Snapshots: LEQEMBI" />
<meta name="twitter:title" content="Drug Trials Snapshots: LEQEMBI" />
<meta name="twitter:creator" content="@US_FDA" />
<meta name="MobileOptimized" content="width" />
<meta name="HandheldFriendly" content="true" />
<meta name="viewport" content="width=device-width, initial-scale=1.0" />
<script type="application/ld+json">{
    "@context": "https://schema.org",
    "@graph": [
        {
            "@type": "Article",
            "headline": "Drug Trials Snapshots: LEQEMBI",
            "name": "Drug Trials Snapshots: LEQEMBI",
            "description": "Drug Trials Snapshots: LEQEMBI",
            "datePublished": "Wed, 04/29/2026 - 07:52",
            "dateModified": "Tue, 10/08/2024 - 00:00",
            "author": {
                "@type": "Organization",
                "name": "Center for Drug Evaluation and Research"
            },
            "publisher": {
                "@type": "Organization",
                "name": "FDA"
            }
        }
    ]
}</script>
<meta property="og:image" content="https://www.fda.gov/themes/custom/preview/img/FDA-Social-Graphic.png" />
<meta name="twitter:image" content="https://www.fda.gov/themes/custom/preview/img/FDA-Social-Graphic.png" />
<link rel="icon" href="/themes/custom/preview/favicon.ico" type="image/vnd.microsoft.icon" />
<link rel="alternate" hreflang="en" href="https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-leqembi" />
<link rel="canonical" href="https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-leqembi" />
<link rel="shortlink" href="https://www.fda.gov/node/423582" />
<script src="/files/google_tag/production/google_tag.script.js?tdm3ib" defer></script>

    <title>Drug Trials Snapshots: LEQEMBI | FDA</title>
    <link rel="stylesheet" media="all" href="/files/css/css_I1lI2DYRy4WvhS49GZC8Z2v9NUFD60djX72-ZNQ0RPY.css?delta=0&amp;language=en&amp;theme=preview&amp;include=eJxNzEsOwjAMRdENBbykKJ9HZeLGJXZA2T2CQWFydUa3NFR2HZF7RfcsWhr9Odgyx045GcIx8GS8aBPNSS7mS7hv4f6YGCtOjjU5Di4Ng34MN1Xv6jA6FT4fo2-vu9YpeAPskjb1" />
<link rel="stylesheet" media="all" href="/files/css/css_B95BD3t88GaU3KJsI8NVEEoAEOpmkrFShtrB0UHHJdY.css?delta=1&amp;language=en&amp;theme=preview&amp;include=eJxNzEsOwjAMRdENBbykKJ9HZeLGJXZA2T2CQWFydUa3NFR2HZF7RfcsWhr9Odgyx045GcIx8GS8aBPNSS7mS7hv4f6YGCtOjjU5Di4Ng34MN1Xv6jA6FT4fo2-vu9YpeAPskjb1" />

    <script src="https://script.crazyegg.com/pages/scripts/0024/3700.js" async></script>
<script src="https://dap.digitalgov.gov/Universal-Federated-Analytics-Min.js?agency=HHS&amp;subagency=FDA&amp;sdor=fda.gov&amp;dclink=true" language="javascript" id="_fed_an_ua_tag"></script>

            <script>window.dataLayer = window.dataLayer || [];function gtag(){dataLayer.push(arguments)};gtag("js", new Date());gtag("set", "developer_id.dMDhkMT", true);gtag("config", "G-273DTKB5QW", {"groups":"default","page_placeholder":"PLACEHOLDER_page_location","allow_ad_personalization_signals":false});</script>
        
  </head>
  <body class="role-anonymous path-node page-node-type-article has-glyphicons">
      <div id="quicklinks" class="sr-only display-on-focus">
        <ul class="list-inline padding-left-3 padding-right-3">
          <li><a href="#main-content" class="btn btn-default margin-top-3" tabindex="1">Skip to main content</a></li>
          <li><a href="#search-form" class="btn btn-default margin-top-3" tabindex="1">Skip to FDA Search</a></li>
          <li><a href="#section-nav" class="btn btn-default margin-top-3" tabindex="1">Skip to in this section menu</a></li>
          <li><a href="#footer" class="btn btn-default margin-top-3" tabindex="1">Skip to footer links</a></li>
        </ul>   
      </div>    <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-M95XGZW" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
      <div class="dialog-off-canvas-main-canvas" data-off-canvas-main-canvas>
       
  <div class="main-container container-fluid">     <div class="row">
                                                               


	
	<header class="lcds-header container-fluid" role="banner">
		                    
			<div class="row us-masthead">                            

				<div class="usa-banner col-xs-12">

					<img class="usa-banner__us-flag" src="/themes/custom/preview/assets/images/US_Flag.png" alt="U.S. flag" />

					<span>An official website of the United States government</span>

				    <a id="USMenuButton" class="collapsed" role="button" aria-expanded="false" aria-controls="USABannerMenu" href="#" data-toggle="collapse" data-target="#USABannerMenu">Here’s how you know <span class="toggle-indicator"> </span></a>

          			<div class="col-xs-12 collapse usa-banner__menu" id="USABannerMenu" aria-labelledby="USMenuButton">


						<div id="gov-banner" class="row usa-banner-content usa-grid usa-accordion-content" aria-hidden="true">
							      <div class="col-xs-12 col-sm-6 col-md-3">
							        <img class="usa-banner-icon usa-media_block-img" src="/themes/custom/preview/assets/images/icon-dot-gov.svg" alt="Dot gov" style="width:3em;">
									<div class="usa-media_block-body">
								      <p><strong>The .gov means it’s official.</strong><br>Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.</p>
								    </div>
							      </div>
							      <div class="col-xs-12 col-sm-6 col-md-3">
							        <img class="usa-banner-icon usa-media_block-img" src="/themes/custom/preview/assets/images/icon-https.svg" alt="SSL" style="width:3em;">
							        <div class="usa-media_block-body">
								         <p><strong>The site is secure.</strong><br> The <strong>https://</strong> ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.</p>
							        </div>
							      </div>
						</div>
					</div>

				</div>
			</div> 			<div class="row fda-masthead">
							<div class="col-xs-4 col-md-8 fda-masthead__fda-logo"> 
					<a href="/" title="FDA Homepage">
            <picture>
              <!-- Set media breakpoint to value equivalent to $screen-md -->
              <source media="(min-width:992px)" srcset="/themes/custom/preview/assets/images/gov-fda-new-white.svg">
              <img src="/themes/custom/preview/assets/images/FDA_Logo_Icon_White.svg" height="40px" alt="U.S. Food and Drug Administration logo">
            </picture>
          </a>
       	</div>
				
        <div class="col-xs-8 col-md-4">
        <ul class="fda-masthead__item-list">
            <li>
                <button id="btn-search" class="btn btn-default btn-sm fda-masthead__btn-search" aria-expanded="false" aria-controls="search-form" title="Open search bar">
					<span class="fa fa-search" aria-hidden="true">&nbsp;</span>
			    	<span class="fda-masthead__btn-label">Search</span>
				</button>
            </li>
            <li>
                <button id="menu-btn" class="btn btn-default btn-sm fda-masthead__btn-menu collapsed" href="#primary-nav" data-toggle="collapse" aria-expanded="true">
                    <span class="fa fa-bars" aria-hidden="true">&nbsp;</span>
                    <span class="fda-masthead__btn-label">Menu</span>
                </button>
            </li>
        </ul>
		</div>
							
						<form class="fda-masthead__search sr-only" id="search-form" aria-hidden="true" role="search" action="/search" method="GET" accept-charset="UTF-8">
							<div class="search-popover" id="search-popover">
								<div class="input-group pull-right" id="search-group">
									<label class="sr-only" for="search-query">Search FDA</label>
									
									<input class="form-control search-input" tabindex="-1" id="search-query" name="s" aria-autocomplete="list" aria-haspopup="true" title="Enter the terms you wish to search for." placeholder="Search FDA"  type="text" /> 
									
									<span class="input-group-btn" id="input-group-btn">
										
										<button type="submit" type="button" class="btn btn-danger search-btn" id="search-btn" tabindex="-1" title="Search"><span class="fa fa-search" aria-hidden="true"><span class="sr-only">Submit search</span></span></button>

									</span>

								</div>
							</div>
																				
						</form>					

			</div> 
		<nav id="primary-nav" class="lcds-primary-nav row collapse">					<div class="col-md-5 col-lg-4">
						<section class="lcds-primary-nav__group lcds-primary-nav__group--bordered">
							<h2 class="lcds-primary-nav__group-heading">Featured</h2>
							<ul class="lcds-primary-nav__list lcds-primary-nav__list--featured">
								<li class="lcds-primary-nav__list-item"><a href="https://www.safetyreporting.hhs.gov/smarthub#/" title="Report a Problem with an FDA Regulated Product">Report a Product Problem</a></li>
	                <li class="lcds-primary-nav__list-item"><a href="/about-fda/contact-fda">Contact FDA</a></li>
	                <li class="lcds-primary-nav__list-item"><a href="/regulatory-information/search-fda-guidance-documents">FDA Guidance Documents</a></li>
	                <li class="lcds-primary-nav__list-item"><a href="/safety/recalls-market-withdrawals-safety-alerts">Recalls, Market Withdrawals and Safety Alerts</a></li>
	                <li class="lcds-primary-nav__list-item"><a href="/news-events/newsroom/press-announcements">Press Announcements</a></li>
	                <li class="lcds-primary-nav__list-item"><a href="/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters">Warning Letters</a></li>
	                <li class="lcds-primary-nav__list-item"><a href="/advisory-committees">Advisory Committees</a></li>
	                <li class="lcds-primary-nav__list-item"><a href="/fda-en-espanol">En Espa&#241ol</a></li>
							</ul>
						</section>
					</div>

					<div class="col-md-7 col-lg-8">
          <section class="lcds-primary-nav__group lcds-primary-nav__group--bordered">
            <h2 class="lcds-primary-nav__group-heading">Products</h2>
            <ul class="lcds-primary-nav__list">
							<li class="lcds-primary-nav__list-item"><a href="/food">Food</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/drugs">Drugs</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/medical-devices">Medical Devices</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/radiation-emitting-products">Radiation-Emitting Products</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/vaccines-blood-biologics">Vaccines, Blood, and Biologics</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/animal-veterinary">Animal and Veterinary</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/cosmetics">Cosmetics</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/tobacco-products">Tobacco Products</a></li>
            </ul>
          </section>
          <section class="lcds-primary-nav__group lcds-primary-nav__group--bordered">
            <h2 class="lcds-primary-nav__group-heading">Topics</h2>
            <ul class="lcds-primary-nav__list">
							<li class="lcds-primary-nav__list-item"><a href="/about-fda">About FDA</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/combination-products">Combination Products</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/regulatory-information">Regulatory Information</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/safety">Safety</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/emergency-preparedness-and-response">Emergency Preparedness</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/international-programs">International Programs</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/news-events">News and Events</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/training-and-continuing-education">Training and Continuing Education</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/inspections-compliance-enforcement-and-criminal-investigations">Inspections and Compliance</a></li>
							<li class="lcds-primary-nav__list-item"><a href="/science-research">Science and Research</a></li>
            </ul>
          </section>
          <section class="lcds-primary-nav__group lcds-primary-nav__group--bordered">
            <h2 class="lcds-primary-nav__group-heading">Information For</h2>
            <ul class="lcds-primary-nav__list">
	            <li class="lcds-primary-nav__list-item"><a href="/consumers">Consumers</a></li>
	            <li class="lcds-primary-nav__list-item"><a href="/patients">Patients</a></li>
	            <li class="lcds-primary-nav__list-item"><a href="/industry">Industry</a></li>
	            <li class="lcds-primary-nav__list-item"><a href="/health-professionals">Health Professionals</a></li>
	            <li class="lcds-primary-nav__list-item"><a href="/federal-state-local-tribal-and-territorial-officials">Federal, State and Local Officials</a></li>
            </ul>
          </section>
					</div>
	      </nav>
    </header>

<div class="col-xs-12 block-prev-message">
	<div data-drupal-messages-fallback class="hidden"></div>

</div>

                              
                                                                     <section id="block-entityviewcontent-15" data-block-plugin-id="entity_view:node" class="block block-ctools block-entity-viewnode clearfix">
  
    

      
    <ol class="lcds-breadcrumb visible-md visible-lg">
          <li >
                  <a href="/">Home</a>
              </li>
          <li >
                  <a href="/drugs">Drugs</a>
              </li>
          <li >
                  <a href="/drugs/development-approval-process-drugs">Development &amp; Approval Process | Drugs</a>
              </li>
          <li >
                  <a href="/drugs/development-approval-process-drugs/drug-approvals-and-databases">Drug Approvals and Databases</a>
              </li>
          <li >
                  <a href="/drugs/drug-approvals-and-databases/drug-trials-snapshots">Drug Trials Snapshots </a>
              </li>
          <li >
                  <a class="current-link">Drug Trials Snapshots: LEQEMBI</a>
              </li>
      </ol>




<ol class="lcds-breadcrumb visible-sm visible-xs">
  <li>
    <a href="/drugs/drug-approvals-and-databases/drug-trials-snapshots" title="Drug Trials Snapshots ">
     Drug Trials Snapshots 
    </a>
  </li>
</ol>

  </section>

<section id="block-entityviewcontent" data-block-plugin-id="entity_view:node" class="block block-ctools block-entity-viewnode clearfix">
  
    

      
<div class="lcds-section-nav-container hidden-md hidden-lg">
<a class="lcds-button--expandable collapsed hidden-md hidden-lg" data-toggle="collapse" href="#section-nav" >In this section</a>

<nav id="section-nav" class="lcds-card lcds-section-nav lcds-section-nav hidden-md hidden-lg collapse">

    <ul class="lcds-section-nav__list">

      <li>

              <a href="/drugs/drug-approvals-and-databases/drug-trials-snapshots" title="Drug Trials Snapshots " class="lcds-section-nav__section-link lcds-section-nav__link lcds-section-nav__parent-link visible-xs-block visible-sm-block">
                                        Drug Trials Snapshots 
                    </a>

                        <div class="views-element-container form-group"><div class="view view-in-this-section view-id-in_this_section view-display-id-block_5 js-view-dom-id-37fa2f7b0320c87423307439413d858dccc1f14297f17f53139d4d2de543eee8">
  
    
      
  
          </div>
</div>


                        <div class="views-element-container form-group"><div class="view view-in-this-section-sub view-id-in_this_section_sub view-display-id-block_2 js-view-dom-id-609801ef3393053ad7f536d9a7bc387d33eecc39f22cf3cc06277ebb617fe6a0">
  
    
      
  
          </div>
</div>


      </li>

    </ul>

</nav>
</div>

  </section>






                                
      <main>

                                 <article id="main-content" class="article main-content container-fluid" role="article">
          
                                                                <header class="row content-header">
                         <section id="block-entityviewcontent-2" data-block-plugin-id="entity_view:node" class="block block-ctools block-entity-viewnode clearfix">
  
    

      
<div class="col-sm-12 col-md-8 col-md-offset-2">

  <h1 class="content-title text-center">Drug Trials Snapshots: LEQEMBI</h1>
  
  	
 
</div>

  </section>






                      </header>
                              
                                                          
                              <aside class="col-md-2" role="complementary">
                  <section id="block-entityviewcontent-3" data-block-plugin-id="entity_view:node" class="block block-ctools block-entity-viewnode clearfix">
  
    

        <div class="region region-">
        <nav id="section-nav"class="lcds-card lcds-section-nav lcds-section-nav--side hidden-xs hidden-sm">
      <ul class="lcds-section-nav__list lcds-section-nav--side__list">
        <li>

                    <a href="/drugs/drug-approvals-and-databases/drug-trials-snapshots" class="lcds-section-nav__link lcds-section-nav--side__link lcds-section-nav__parent-link lcds-section-nav--side__parent-link">
                                        Drug Trials Snapshots 
                      </a>

          
                        <div class="views-element-container form-group"><div class="view view-in-this-section view-id-in_this_section view-display-id-block_4 js-view-dom-id-18e1787511d15603478deb99b88f57a3d92f247b1b7c4af4e38e6c861314fb5c">
  
    
      
  
          </div>
</div>


                        <div class="views-element-container form-group"><div class="view view-in-this-section-sub view-id-in_this_section_sub view-display-id-block_1 js-view-dom-id-76d5e7f03adfda4c13322e77358fc472b1b449fcd9f05b38c9178f8a302b2f3c">
  
    
      
  
          </div>
</div>


        </li>
      </ul>
    </nav>
    </div>

  </section>


                </aside>
              
                                                          
              <div class="col-md-8" role="main">

                            
                            
                            
                            
                                              
  
<p></p><div type="danger">
	<div class="alert alert-danger">
	  <p><strong>HOW TO USE THIS SNAPSHOT</strong><br>The information provided in Snapshots highlights who participated in the key clinical trials that supported the original FDA approval of this drug, and whether there were differences among sex, race, age, and ethnic groups. The “MORE INFO” bar shows more detailed, technical content for each section. The Snapshot is intended as one tool for consumers to use when discussing the risks and benefits of the drugs.</p><p><strong>LIMITATIONS OF THIS SNAPSHOT:</strong><br>Do not rely on Snapshots to make decisions regarding medical care. Always speak to your healthcare provider about the benefits and risks of a drug.</p><p>Some of the information in this Snapshot is for presentation purposes and does not represent the approved conditions of use of this drug. Refer to the LEQEMBI <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761269Orig1s001lbl.pdf">Prescribing Information</a> for all of the approved conditions of use of this drug (e.g., indication(s), population(s), dosing regimen(s), safety information).</p><p>Snapshots are limited to the information available at the time of the original approval of the drug and do not provide information on who participated in clinical trials that supported later approvals for additional uses of the drug (if applicable).</p><p>
	</p></div>
</div>
<p><strong>LEQEMBI (lecanemab-irmb)</strong><br>Leh kem’ bee<br><strong>Eisai Inc.</strong><br><strong>Original Approval date</strong>: January 6, 2023</p><hr><h2>DRUG TRIALS SNAPSHOT SUMMARY:</h2><p><strong>What is the drug for?</strong></p><p>LEQEMBI is a prescription medicine used to treat people with Alzheimer’s disease. Alzheimer’s disease is a common degenerative disease of the brain that starts with mild thinking, judging, and memory problems and progresses to dementia and death. Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in the clinical trials.</p><p><strong>How is this drug used?</strong></p><p>LEQEMBI is administered as an intravenous (IV) infusion over approximately one hour every two weeks.</p><p><strong>Who participated in the clinical trials?</strong></p><p>The FDA approved LEQEMBI based on evidence from one main clinical trial of 1,795 patients with Alzheimer’s disease. The trial was conducted at 253 sites in 13 countries in North America, Europe, Asia, and Australia. Fifty-three percent of patients were enrolled in the United States. The trial assessed both efficacy and safety.</p><p><strong>How were the trials designed?</strong></p><p>The benefits and side effects of LEQEMBI were evaluated in one main clinical trial of patients with Alzheimer’s disease. Patients received LEQEMBI or placebo for 76 weeks. Neither the patients nor the health care providers knew which treatment was being given until the trial was completed.</p><p>The benefit of LEQEMBI was evaluated on several clinical scales including the Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB), the Alzheimer’s Disease Assessment Scale - Cognitive subscale (ADAS-Cog 14), and the Alzheimer’s Disease Cooperative Study - Activities of Daily Living Scale for Mild Cognitive Impairment (ADCS MCI-ADL).</p><p></p><div class=" panel-group" id="accordion_669747" role="tablist" aria-multiselectable="true"><p>   
</p><div title="MORE INFO" open="no" class=" panel panel-default fda-accordion-panel">
	<div class="panel-heading" role="tab" id="heading_69fa4766a0e74">
		<h2 class="panel-title">
			<a role="button" class="collapsed" data-toggle="collapse" data-parent href="#69fa4766a0e74" aria-controls="69fa4766a0e74">MORE INFO</a>
		</h2>
	</div>
    <div id="69fa4766a0e74" class="panel-collapse collapse " role="tabpanel" aria-labelledby="heading_69fa4766a0e74">
		<div class="panel-body">
			<p><strong>How were the trials designed?</strong></p><p>The efficacy and safety of LEQEMBI were evaluated in a double-blind, placebo-controlled, parallel-group, randomized study in patients with Alzheimer’s disease (patients with confirmed presence of amyloid pathology and mild cognitive impairment or mild dementia stage of disease, consistent with Stage 3 and Stage 4 Alzheimer’s disease). Patients were enrolled with a Clinical Dementia Rating (CDR) global score of 0.5 or 1.0 and a Memory Box score of 0.5 or greater. All patients had a Mini-Mental State Examination (MMSE) score of ≥22 and ≤30 and had objective impairment in episodic memory as indicated by at least one standard deviation below age-adjusted mean in the Wechsler-Memory Scale-IV Logical Memory II (subscale) (WMS-IV LMII). Patients were enrolled with or without concomitant approved therapies (cholinesterase inhibitors and the N-methyl-D-aspartate antagonist memantine) for Alzheimer’s disease.</p><p>The study included a 60-day screening period, an 18-month (78-week) placebo-controlled period, and a safety follow-up period of 3 months after the final dose. Patients were randomized to placebo or 10 mg/kg LEQEMBI once every two weeks in a 1:1 ratio in the placebo-controlled period. Patients who completed the placebo-controlled period and met the inclusion or exclusion criteria had the option to directly enter the open-label extension phase of the study.</p><p>The primary efficacy endpoint was change from baseline at 18 months in the CDR-SB. Key secondary endpoints included change from baseline at 18 months for the following measures: amyloid Positron Emission Tomography (PET) using Centiloids, ADAS-Cog14, and ADCS MCI-ADL.</p><p>
		</p></div>
	</div>
</div><p></p></div><h2>DEMOGRAPHICS SNAPSHOT</h2><p>Figure 1 summarizes how many male and female patients were enrolled in the clinical trial used to evaluate the efficacy of LEQEMBI.</p><p><strong>Figure 1. Baseline Demographics by Sex</strong></p><div alt="Pie chart summarizing how many male and female patients were in the clinical trial. In total, 857 (48%) male patients and 938 (52%) female patients participated in the clinical trial." title="LEQEMBI Figure 1 Baseline Demographics by Sex" data-langcode="en" data-entity-type="media" data-entity-uuid="667ad15f-896f-414f-848d-d30fe243ceb3" data-embed-button="media_browser" data-entity-embed-display="media_image" data-entity-embed-display-settings="Array" class="embedded-entity">  <img loading="lazy" src="/files/LEQEMBI%20Figure%201%20Baseline%20Demographics%20by%20Sex.png" alt="Pie chart summarizing how many male and female patients were in the clinical trial. In total, 857 (48%) male patients and 938 (52%) female patients participated in the clinical trial." title="LEQEMBI Figure 1 Baseline Demographics by Sex" class="img-responsive">

</div>
<p><small>Source: Adapted from FDA Review</small></p><p>Figure 2 summarizes how many patients by race were enrolled in the clinical trial used to evaluate the efficacy of LEQEMBI.</p><p><strong>Figure 2. Baseline Demographics by Race</strong></p><div alt="Pie chart summarizing how many White, Black or African American, Asian, American Indian or Alaskan Native, Native Hawaiian or other Pacific Islander, missing, and other patients were in the clinical trial. In total, 1,381 (76.9%) White patients, 47 (2.6%) Black or African American patients, 303 (16.9%) Asian, 2 (0.1%) American Indian or Alaskan Native patients, 1 (0.1%) Native Hawaiian or other Pacific Islander patients, 28 (1.6%) patients with missing race, and 33 (1.8%) other patients participated in the clinical trial." title="LEQEMBI Figure 2 Baseline Demographics by Race" data-langcode="en" data-entity-type="media" data-entity-uuid="aa661753-9003-4e91-aafa-feb80cb5c970" data-embed-button="media_browser" data-entity-embed-display="media_image" data-entity-embed-display-settings="Array" class="embedded-entity">  <img loading="lazy" src="/files/LEQEMBI%20Figure%202%20Baseline%20Demographics%20by%20Race.png" alt="Pie chart summarizing how many White, Black or African American, Asian, American Indian or Alaskan Native, Native Hawaiian or other Pacific Islander, missing, and other patients were in the clinical trial. In total, 1,381 (76.9%) White patients, 47 (2.6%) Black or African American patients, 303 (16.9%) Asian, 2 (0.1%) American Indian or Alaskan Native patients, 1 (0.1%) Native Hawaiian or other Pacific Islander patients, 28 (1.6%) patients with missing race, and 33 (1.8%) other patients participated in the clinical trial." title="LEQEMBI Figure 2 Baseline Demographics by Race" class="img-responsive">

</div>
<p><small>Source: Adapted from FDA Review</small></p><p>Figure 3 summarizes how many patients by age were enrolled in the clinical trial used to evaluate the efficacy of LEQEMBI.</p><p><strong>Figure 3. Baseline Demographics by Age</strong></p><div alt="Pie chart summarizing how many patients by age were in the clinical trial. In total, 353 (20%) patients younger than 65 years of age, 774 (43%) patients between 65 and 74 years of age, and 668 (37%) patients 75 years of age and older participated in the clinical trial." title="LEQEMBI Figure 3 Baseline Demographics by Age" data-langcode="en" data-entity-type="media" data-entity-uuid="79358293-3aff-4a73-8e55-1a54e8560d45" data-embed-button="media_browser" data-entity-embed-display="media_image" data-entity-embed-display-settings="Array" class="embedded-entity">  <img loading="lazy" src="/files/LEQEMBI%20Figure%203%20Baseline%20Demographics%20by%20Age.png" alt="Pie chart summarizing how many patients by age were in the clinical trial. In total, 353 (20%) patients younger than 65 years of age, 774 (43%) patients between 65 and 74 years of age, and 668 (37%) patients 75 years of age and older participated in the clinical trial." title="LEQEMBI Figure 3 Baseline Demographics by Age" class="img-responsive">

</div>
<p><small>Source: Adapted from FDA Review</small></p><p>Figure 4 summarizes how many patients by ethnicity were enrolled in the clinical trial used to evaluate the efficacy of LEQEMBI.</p><p><strong>Figure 4. Baseline Demographics by Ethnicity</strong></p><div alt="Pie chart summarizing how many Hispanic, not Hispanic, and unknown patients were in the clinical trial. In total, 231 (13%) Hispanic or Latino patients, 1,503 (84%) not Hispanic or Latino patients, and 61 (3%) unknown patients participated in the clinical trial." title="LEQEMBI Figure 4 Baseline Demographics by Ethnicity" data-langcode="en" data-entity-type="media" data-entity-uuid="bb0bb0c0-a8d0-4e86-b70f-43dc479e7794" data-embed-button="media_browser" data-entity-embed-display="media_image" data-entity-embed-display-settings="Array" class="embedded-entity">  <img loading="lazy" src="/files/LEQEMBI%20Figure%204%20Baseline%20Demographics%20by%20Ethnicity.png" alt="Pie chart summarizing how many Hispanic, not Hispanic, and unknown patients were in the clinical trial. In total, 231 (13%) Hispanic or Latino patients, 1,503 (84%) not Hispanic or Latino patients, and 61 (3%) unknown patients participated in the clinical trial." title="LEQEMBI Figure 4 Baseline Demographics by Ethnicity" class="img-responsive">

</div>
<p><small>Source: Adapted from FDA Review</small></p><p></p><div class=" panel-group" id="accordion_670670" role="tablist" aria-multiselectable="true"><p>   
</p><div title="MORE INFO" open="no" class=" panel panel-default fda-accordion-panel">
	<div class="panel-heading" role="tab" id="heading_69fa4766a387b">
		<h2 class="panel-title">
			<a role="button" class="collapsed" data-toggle="collapse" data-parent href="#69fa4766a387b" aria-controls="69fa4766a387b">MORE INFO</a>
		</h2>
	</div>
    <div id="69fa4766a387b" class="panel-collapse collapse " role="tabpanel" aria-labelledby="heading_69fa4766a387b">
		<div class="panel-body">
			<p><strong>Who participated in the trials?</strong></p><p><strong>Table 1. Baseline Demographics, Randomized Population</strong></p><div class="table-responsive"><table class="table table-responsive table-bordered table-striped" border="1" cellpadding="4" cellspacing="0" summary="Table 1. Baseline Demographics, Randomized Population" width="100%"><thead><tr><th scope="col">Demographic</th><th scope="col"><p class="text-align-right">Placebo<br>N=897</p></th><th scope="col"><p class="text-align-right">LEQEMBI<br>N=898</p></th><th scope="col"><p class="text-align-right">Total<br>N=1795</p></th></tr><tr><th colspan="4" scope="rowgroup">Sex, n (%)</th></tr><tr><th colspan="4" scope="rowgroup">Age</th></tr><tr><th colspan="4" scope="rowgroup">Age group, years, n (%)</th></tr><tr><th colspan="4" scope="rowgroup">Race, n (%)</th></tr><tr><th colspan="4" scope="rowgroup">Ethnicity, n (%)</th></tr></thead><tbody><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;Male</th><td><p class="text-align-right">421 (46.9)</p></td><td><p class="text-align-right">436 (48.6)</p></td><td><p class="text-align-right">857 (47.7)</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;Female</th><td><p class="text-align-right">476 (53.1)</p></td><td><p class="text-align-right">462 (51.4)</p></td><td><p class="text-align-right">938 (52.3)</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;Mean (SD)</th><td><p class="text-align-right">71.1 (7.8)</p></td><td><p class="text-align-right">71.4 (7.9)</p></td><td><p class="text-align-right">71.3 (7.8)</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;Median (min, max)</th><td><p class="text-align-right">72.0 (50.0, 90.0)</p></td><td><p class="text-align-right">72.0 (50.0, 90.0)</p></td><td><p class="text-align-right">72.0 (50.0, 90.0)</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;&lt;65</th><td><p class="text-align-right">178 (19.8)</p></td><td><p class="text-align-right">175 (19.5)</p></td><td><p class="text-align-right">353 (19.7)</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;65 to 74</th><td><p class="text-align-right">391 (43.6)</p></td><td><p class="text-align-right">383 (42.7)</p></td><td><p class="text-align-right">774 (43.1)</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;≥75</th><td><p class="text-align-right">328 (36.6)</p></td><td><p class="text-align-right">340 (37.9)</p></td><td><p class="text-align-right">668 (37.2)</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;White</th><td><p class="text-align-right">696 (77.6)</p></td><td><p class="text-align-right">685 (76.3)</p></td><td><p class="text-align-right">1381 (76.9)</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;Black or African American</th><td><p class="text-align-right">25 (2.8)</p></td><td><p class="text-align-right">22 (2.4)</p></td><td><p class="text-align-right">47 (2.6)</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;Asian</th><td><p class="text-align-right">150 (16.7)</p></td><td><p class="text-align-right">153 (17.0)</p></td><td><p class="text-align-right">303 (16.9)</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;American Indian or Alaskan Native</th><td><p class="text-align-right">2 (0.2)</p></td><td><p class="text-align-right">0</p></td><td><p class="text-align-right">2 (0.1)</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;Native Hawaiian or other Pacific Islander</th><td><p class="text-align-right">0</p></td><td><p class="text-align-right">1 (0.1)</p></td><td><p class="text-align-right">1 (0.1)</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;Missing</th><td><p class="text-align-right">12 (1.3)</p></td><td><p class="text-align-right">16 (1.8)</p></td><td><p class="text-align-right">28 (1.6)</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;Other</th><td><p class="text-align-right">12 (1.3)</p></td><td><p class="text-align-right">21 (2.3)</p></td><td><p class="text-align-right">33 (1.8)</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;Not Hispanic or Latino</th><td><p class="text-align-right">759 (84.6)</p></td><td><p class="text-align-right">744 (82.9)</p></td><td><p class="text-align-right">1503 (83.7)</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;Hispanic or Latino</th><td><p class="text-align-right">114 (12.7)</p></td><td><p class="text-align-right">117 (13.0)</p></td><td><p class="text-align-right">231 (12.9)</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;Missing</th><td><p class="text-align-right">24 (2.7)</p></td><td><p class="text-align-right">37 (4.1)</p></td><td><p class="text-align-right">61 (3.4)</p></td></tr></tbody></table></div><p><small>Source: Adapted from FDA Review</small><br><small>Abbreviations: SD, standard deviation</small></p><p>
		</p></div>
	</div>
</div><p></p></div><p><strong>What are the benefits of this drug?</strong></p><p>Patients treated with LEQEMBI demonstrated a reduction in cognitive and functional decline as measured by several clinical scales.</p><p></p><div class=" panel-group" id="accordion_670992" role="tablist" aria-multiselectable="true"><p>   
</p><div title="MORE INFO" open="no" class=" panel panel-default fda-accordion-panel">
	<div class="panel-heading" role="tab" id="heading_69fa4766a3bfb">
		<h2 class="panel-title">
			<a role="button" class="collapsed" data-toggle="collapse" data-parent href="#69fa4766a3bfb" aria-controls="69fa4766a3bfb">MORE INFO</a>
		</h2>
	</div>
    <div id="69fa4766a3bfb" class="panel-collapse collapse " role="tabpanel" aria-labelledby="heading_69fa4766a3bfb">
		<div class="panel-body">
			<p><strong>What are the benefits of this drug (results of trials used to assess efficacy)?</strong></p><p>The primary efficacy outcome was change from baseline at 18 months in the CDR-SB. Other endpoints included change from baseline at 18 months for the ADAS-Cog14 and ADCS MCI-ADL.</p><p>Patients treated with LEQEMBI demonstrated a statistically significant reduction in clinical decline on CDR-SB compared to placebo at Month 18 (-0.45, [-27%] p&lt;0.0001). Statistically significant differences (p&lt;0.01) between treatment groups were also seen in the results for ADAS-Cog14 and ADCS MCI-ADL at 18 months.</p><p><strong>Table 2. Efficacy Results, Efficacy Population</strong></p><div class="table-responsive"><table class="table table-responsive table-bordered table-striped" border="1" cellpadding="4" cellspacing="0" summary="Table 2. Efficacy Results, Efficacy Population" width="100%"><thead><tr><th scope="col">Clinical Endpoint</th><th scope="col"><p class="text-align-right">LEQEMBI</p></th><th scope="col"><p class="text-align-right">Placebo</p></th></tr></thead><tbody><tr><th scope="rowgroup">CDR-SB</th><td><p class="text-align-right">N=859</p></td><td><p class="text-align-right">N=875</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;Mean baseline</th><td><p class="text-align-right">3.17</p></td><td><p class="text-align-right">3.22</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;Adjusted mean change from baseline at 18 months (%)</th><td><p class="text-align-right">1.21</p></td><td><p class="text-align-right">1.66</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;Difference from placebo</th><td colspan="2"><p class="text-align-center">-0.45 (-27%)</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;p-value</th><td colspan="2"><p class="text-align-center">p&lt;0.0001</p></td></tr><tr><th scope="rowgroup">ADAS-Cog14</th><td><p class="text-align-right">N=854</p></td><td><p class="text-align-right">N=872</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;Mean baseline</th><td><p class="text-align-right">24.45</p></td><td><p class="text-align-right">24.37</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;Adjusted mean change from baseline at 18 months (%)</th><td><p class="text-align-right">4.140</p></td><td><p class="text-align-right">5.581</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;Difference from placebo</th><td colspan="2"><p class="text-align-center">-1.442 (-26%)</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;p-value</th><td colspan="2"><p class="text-align-center">p=0.00065</p></td></tr><tr><th scope="rowgroup">ADCS MCI-ADL</th><td><p class="text-align-right">N=783</p></td><td><p class="text-align-right">N=796</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;Mean baseline</th><td><p class="text-align-right">41.2</p></td><td><p class="text-align-right">40.9</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;Adjusted mean change from baseline at 18 months</th><td><p class="text-align-right">-3.5</p></td><td><p class="text-align-right">-5.5</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;Difference from placebo</th><td colspan="2"><p class="text-align-center">2.0 (-37%)</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;p-value</th><td colspan="2"><p class="text-align-center">p&lt;0.0001</p></td></tr></tbody></table></div><p><small>Source: Adapted from LEQEMBI Prescribing Information</small><br><small>Abbreviations: ADAS-Cog14, Alzheimer’s Disease Assessment Scale - Cognitive subscale; ADCS MCI-ADL, Alzheimer’s Disease Cooperative Study - Activities of Daily Living Scale for Mild Cognitive Impairment; CDR-SB, Clinical Dementia Rating Scale - Sum of Boxes</small></p><p>
		</p></div>
	</div>
</div><p></p></div><p><strong>Were there any differences in how well the drug worked in clinical trials among sex, race and age?</strong></p><ul><li><strong>Sex</strong>: The observed effect was larger in males compared to females. Because of limited data, this difference may be due to chance.</li><li><strong>Race</strong>: The number of patients of races other than White was small; therefore, differences in how LEQEMBI worked among races could not be determined.</li><li><strong>Age</strong>: The observed effect was largest in patients older than 75 years of age. Because of limited data, this difference may be due to chance.</li></ul><p></p><div class=" panel-group" id="accordion_671270" role="tablist" aria-multiselectable="true"><p>   
</p><div title="MORE INFO" open="no" class=" panel panel-default fda-accordion-panel">
	<div class="panel-heading" role="tab" id="heading_69fa4766a3d58">
		<h2 class="panel-title">
			<a role="button" class="collapsed" data-toggle="collapse" data-parent href="#69fa4766a3d58" aria-controls="69fa4766a3d58">MORE INFO</a>
		</h2>
	</div>
    <div id="69fa4766a3d58" class="panel-collapse collapse " role="tabpanel" aria-labelledby="heading_69fa4766a3d58">
		<div class="panel-body">
			<p><strong>Were there any differences in how well the drug worked in clinical trials among sex, race, and age groups?</strong></p><p>The subgroup results of CDR-SB change from baseline at 18 months were generally consistent with the results of the overall population. The number of patients of races other than White was small; therefore, differences in how LEQEMBI worked among races have considerable uncertainty.</p><p><strong>Table 3. CDR-SB Change From Baseline at 18 Months by Subgroup, Efficacy Population</strong></p><div class="table-responsive"><table class="table table-responsive table-bordered table-striped" border="1" cellpadding="4" cellspacing="0" summary="Table 3. CDR-SB Change From Baseline at 18 Months by Subgroup, Efficacy Population" width="100%"><thead><tr><th scope="col">Subgroup</th><th scope="col"><p class="text-align-right">LEQEMBI<br>N=859<br>Change From<br>Baseline (SE)</p></th><th scope="col"><p class="text-align-right">Placebo<br>N=875<br>Change From<br>Baseline (SE)</p></th><th scope="col"><p class="text-align-right">Adjusted Mean<br>Difference (95% CI)</p></th></tr><tr><th colspan="4" scope="rowgroup">Sex</th></tr><tr><th colspan="4" scope="rowgroup">Race</th></tr><tr><th colspan="4" scope="rowgroup">Age, years</th></tr><tr><th colspan="4" scope="rowgroup">Ethnicity</th></tr></thead><tbody><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;Female</th><td><p class="text-align-right">1.5 (0.1)</p></td><td><p class="text-align-right">1.7 (0.1)</p></td><td><p class="text-align-right">-0.2 (-0.5, 0.1)</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;Male</th><td><p class="text-align-right">0.9 (0.1)</p></td><td><p class="text-align-right">1.7 (0.1)</p></td><td><p class="text-align-right">-0.7 (-1.0, -0.4)</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;Asian</th><td><p class="text-align-right">1.7 (0.3)</p></td><td><p class="text-align-right">2.0 (0.3)</p></td><td><p class="text-align-right">-0.3 (-0.9, 0.2)</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;Black or African American</th><td><p class="text-align-right">-0.1 (0.5)</p></td><td><p class="text-align-right">0.7 (0.5)</p></td><td><p class="text-align-right">-0.8 (-2.2, 0.6)</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;White</th><td><p class="text-align-right">1.0 (0.2)</p></td><td><p class="text-align-right">1.5 (0.2)</p></td><td><p class="text-align-right">-0.5 (-0.7, -0.2)</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;&lt;65</th><td><p class="text-align-right">1.4 (0.2)</p></td><td><p class="text-align-right">1.5 (0.2)</p></td><td><p class="text-align-right">-0.1 (-0.6, 0.4)</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;≥65 to &lt;75</th><td><p class="text-align-right">1.2 (0.1)</p></td><td><p class="text-align-right">1.6 (0.1)</p></td><td><p class="text-align-right">-0.4 (-0.7, 0.0)</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;≥75</th><td><p class="text-align-right">1.1 (0.1)</p></td><td><p class="text-align-right">1.8 (0.1)</p></td><td><p class="text-align-right">-0.7 (-1.1, -0.4)</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;Hispanic or Latino</th><td><p class="text-align-right">0.0 (0.2)</p></td><td><p class="text-align-right">0.5 (0.2)</p></td><td><p class="text-align-right">-0.5 (-1.1, 0.1)</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;Not Hispanic or Latino</th><td><p class="text-align-right">1.4 (0.1)</p></td><td><p class="text-align-right">1.8 (0.1)</p></td><td><p class="text-align-right">-0.5 (-0.7, -0.2)</p></td></tr></tbody></table></div><p><small>Source: Adapted from FDA Review</small><br><small>The MMRM used to estimate adjusted means included baseline CDR-SB as a covariate, with treatment group, visit, stratification variables (i.e., clinical subgroup, use of AD symptomatic medication at baseline [yes, no], APOE4 carrier status [carriers, noncarriers], and geographical region [North America, Europe, and Asia Pacific]), baseline CDR-SB-by-visit, and treatment group-by-visit interaction as fixed effects. Subgroup effects were estimated by adding fixed interaction effects between the subgroup variable and treatment and visit variables to the primary MMRM model. An increase from baseline indicates worsening of symptoms.</small><br><small>Abbreviations: AD, Alzheimer’s Disease; CDR-SB, Clinical Dementia Rating Scale - Sum of Boxes; CI, confidence interval; MMRM, mixed model for repeated measures; SE, standard error</small></p><p>
		</p></div>
	</div>
</div><p></p></div><p><strong>What are the possible side effects?</strong></p><p>LEQEMBI can cause serious side effects.</p><p>The most common side effects of LEQEMBI include amyloid-related imaging abnormalities (ARIA) and infusion-related reactions.</p><p>ARIA refers to temporary swelling in areas of the brain (ARIA-E), or small spots of bleeding in or on the surface of the brain (ARIA-H). The swelling in areas of the brain usually resolves over time, while the small spots of bleeding in or on the surface of the brain may not resolve. Most people with ARIA do not get symptoms; however, some people, especially those with swelling in the brain may have symptoms, such as headache, nausea, confusion, difficulty walking, dizziness, seizures, and vision changes. Some of these symptoms may be serious and life-threatening. While ARIA may occur any time during treatment with LEQEMBI, it has most frequently been observed during the first 14 weeks of treatment.</p><p>Some people may also develop larger areas of bleeding in the brain while taking LEQEMBI which also may be serious and life-threatening. Some people may be at a higher risk of developing bleeding in the brain if they are taking medicines to reduce blood clots from forming (i.e., antithrombotic medications) while receiving LEQEMBI.</p><p>Some people have a genetic risk factor (homozygous apolipoprotein E [ApoE] gene carriers) that may cause an increased risk for serious ARIA. Patients should discuss the risk of ARIA with different ApoE genotypes and the implications of genetic testing results with their health care providers.</p><p>Some patients taking LEQEMBI may experience infusion-related reactions. An infusion-related reaction is a side effect that may occur during or shortly after the infusion of LEQEMBI. The symptoms of an infusion-related reaction may include fever, flu-like symptoms (chills, body aches, feeling shaky and joint pain), nausea, vomiting, dizziness and lightheadedness, changes in heart rate, difficulty breathing.</p><p>LEQEMBI can cause allergic reactions that may be serious.</p><p></p><div class=" panel-group" id="accordion_671542" role="tablist" aria-multiselectable="true"><p>   
</p><div title="MORE INFO" open="no" class=" panel panel-default fda-accordion-panel">
	<div class="panel-heading" role="tab" id="heading_69fa4766a3e4c">
		<h2 class="panel-title">
			<a role="button" class="collapsed" data-toggle="collapse" data-parent href="#69fa4766a3e4c" aria-controls="69fa4766a3e4c">MORE INFO</a>
		</h2>
	</div>
    <div id="69fa4766a3e4c" class="panel-collapse collapse " role="tabpanel" aria-labelledby="heading_69fa4766a3e4c">
		<div class="panel-body">
			<p><strong>What are the possible side effects (results of trials used to assess safety)?</strong></p><p>The most common side effects that were seen in patients taking LEQEMBI in the pivotal study conducted with LEQEMBI are shown below in Table 4.</p><p><strong>Table 4. Side Effects Reported in at Least 5% of Patients Treated With LEQEMBI and at Least 2% Higher Than Placebo</strong></p><div class="table-responsive"><table class="table table-responsive table-bordered table-striped" border="1" cellpadding="4" cellspacing="0" summary="Table 4. Side Effects Reported in at Least 5% of Patients Treated With LEQEMBI and at Least 2% Higher Than Placebo" width="100%"><thead><tr><th scope="col">Adverse Reactions</th><th scope="col"><p class="text-align-right">LEQEMBI<br>N=898<br>%</p></th><th scope="col"><p class="text-align-right">Placebo<br>N=897<br>%</p></th></tr></thead><tbody><tr><th scope="row">Infusion-related reactions</th><td><p class="text-align-right">26</p></td><td><p class="text-align-right">7</p></td></tr><tr><th scope="row">ARIA-H</th><td><p class="text-align-right">14</p></td><td><p class="text-align-right">8</p></td></tr><tr><th scope="row">ARIA-E</th><td><p class="text-align-right">13</p></td><td><p class="text-align-right">2</p></td></tr><tr><th scope="row">Headache</th><td><p class="text-align-right">11</p></td><td><p class="text-align-right">8</p></td></tr><tr><th scope="row">Superficial siderosis of central nervous system</th><td><p class="text-align-right">6</p></td><td><p class="text-align-right">3</p></td></tr><tr><th scope="row">Rash<sup>1</sup></th><td><p class="text-align-right">6</p></td><td><p class="text-align-right">4</p></td></tr><tr><th scope="row">Nausea or vomiting</th><td><p class="text-align-right">6</p></td><td><p class="text-align-right">4</p></td></tr></tbody></table></div><p><small>Source: Adapted from LEQEMBI Prescribing Information</small><br><small><sup>1</sup> Rash includes acne, erythema, infusion site rash, injection site rash, rash, rash erythematous, rash pruritic, skin reactions, and urticaria.</small><br><small>Abbreviations: ARIA-E, amyloid-related imaging abnormalities with edema; ARIA-H, amyloid-related imaging abnormalities with hemosiderin deposition</small></p><p>Less common side effects seen during LEQEMBI treatment include atrial fibrillation, an abnormal rhythm of the heart, which occurred in 3% of patients treated with LEQEMBI compared to 2% in patients on placebo.</p><p>
		</p></div>
	</div>
</div><p></p></div><p><strong>Were there any differences in side effects of the clinical trials among sex, race, and age?</strong></p><p>The small number in most of these subgroup analyses limit conclusions about the significance of these differences.</p><ul><li><strong>Sex</strong>: While ARIA-E and ARIA-H rates were comparable between males and females, infusion-related reactions were slightly lower, and headache was slightly higher in females compared to males.</li><li><strong>Race</strong>: The number of patients of races other than White was small; therefore, the interpretation of the occurrence of side effects by race was limited.</li><li><strong>Age</strong>: The overall occurrence of side effects was similar in patients younger and older than 65 years of age. Those over 80 years old appeared to have lower rates of ARIA-E and headache; however, the conclusions about the differences are limited by the small numbers of patients over 80 years old.</li></ul><p></p><div class=" panel-group" id="accordion_671784" role="tablist" aria-multiselectable="true"><p>   
</p><div title="MORE INFO" open="no" class=" panel panel-default fda-accordion-panel">
	<div class="panel-heading" role="tab" id="heading_69fa4766a3f6b">
		<h2 class="panel-title">
			<a role="button" class="collapsed" data-toggle="collapse" data-parent href="#69fa4766a3f6b" aria-controls="69fa4766a3f6b">MORE INFO</a>
		</h2>
	</div>
    <div id="69fa4766a3f6b" class="panel-collapse collapse " role="tabpanel" aria-labelledby="heading_69fa4766a3f6b">
		<div class="panel-body">
			<p><strong>Were there any differences in side effects of the clinical trials among sex, race, and age groups?</strong></p><p><strong>Table 5. Side Effects by Subgroup, Safety Population</strong></p><div class="table-responsive"><table class="table table-responsive table-bordered table-striped" border="1" cellpadding="4" cellspacing="0" summary="Table 5. Side Effects by Subgroup, Safety Population" width="100%"><thead><tr><th rowspan="2" scope="col">Subgroup</th><th colspan="5"><p class="text-align-center">LEQEMBI, N=898</p></th></tr><tr><th scope="col"><p class="text-align-right">ARIA-E<br>%</p></th><th scope="col"><p class="text-align-right">ARIA-H<br>%</p></th><th scope="col"><p class="text-align-right">Headache<br>%</p></th><th scope="col"><p class="text-align-right">Infusion Related<br>Reaction<br>%</p></th><th scope="col"><p class="text-align-right">Overall TEAEs<br>%</p></th></tr><tr><th colspan="6" scope="rowgroup">Sex</th></tr><tr><th colspan="6" scope="rowgroup">Age, years</th></tr><tr><th colspan="6" scope="rowgroup">Race</th></tr><tr><th colspan="6" scope="rowgroup">Disposition</th></tr><tr><th colspan="6" scope="rowgroup">Region</th></tr><tr><th colspan="6" scope="rowgroup">BMI</th></tr></thead><tbody><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;Males (n=436)</th><td><p class="text-align-right">12</p></td><td><p class="text-align-right">15</p></td><td><p class="text-align-right">9</p></td><td><p class="text-align-right">28</p></td><td><p class="text-align-right">90</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;Females (n=462)</th><td><p class="text-align-right">13</p></td><td><p class="text-align-right">13</p></td><td><p class="text-align-right">13</p></td><td><p class="text-align-right">24</p></td><td><p class="text-align-right">80</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;&lt;65 (n=175)</th><td><p class="text-align-right">14</p></td><td><p class="text-align-right">9</p></td><td><p class="text-align-right">14</p></td><td><p class="text-align-right">24</p></td><td><p class="text-align-right">87</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;65 to 80 (n=593)</th><td><p class="text-align-right">14</p></td><td><p class="text-align-right">16</p></td><td><p class="text-align-right">12</p></td><td><p class="text-align-right">27</p></td><td><p class="text-align-right">90</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;&gt;80 (n=130)</th><td><p class="text-align-right">5</p></td><td><p class="text-align-right">13</p></td><td><p class="text-align-right">5</p></td><td><p class="text-align-right">27</p></td><td><p class="text-align-right">88.5</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;White (n=685)</th><td><p class="text-align-right">14</p></td><td><p class="text-align-right">15</p></td><td><p class="text-align-right">13</p></td><td><p class="text-align-right">28</p></td><td><p class="text-align-right">90</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;African American (n=22)</th><td><p class="text-align-right">9</p></td><td><p class="text-align-right">14</p></td><td><p class="text-align-right">9</p></td><td><p class="text-align-right">9</p></td><td><p class="text-align-right">86</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;Asian (n=153)</th><td><p class="text-align-right">6.5</p></td><td><p class="text-align-right">10.5</p></td><td><p class="text-align-right">5</p></td><td><p class="text-align-right">12</p></td><td><p class="text-align-right">84</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;Other (including missing) (n=38)</th><td><p class="text-align-right">21</p></td><td><p class="text-align-right">18</p></td><td><p class="text-align-right">16</p></td><td><p class="text-align-right">67</p></td><td><p class="text-align-right">97</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;MCI (n=552)</th><td><p class="text-align-right">13</p></td><td><p class="text-align-right">14</p></td><td><p class="text-align-right">12</p></td><td><p class="text-align-right">26</p></td><td><p class="text-align-right">88</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;AD (n=346)</th><td><p class="text-align-right">12</p></td><td><p class="text-align-right">14.5</p></td><td><p class="text-align-right">10</p></td><td><p class="text-align-right">27</p></td><td><p class="text-align-right">90</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;North America (n=537)</th><td><p class="text-align-right">13</p></td><td><p class="text-align-right">14.5</p></td><td><p class="text-align-right">11</p></td><td><p class="text-align-right">29</p></td><td><p class="text-align-right">89</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;Europe (n=215)</th><td><p class="text-align-right">15</p></td><td><p class="text-align-right">15</p></td><td><p class="text-align-right">17</p></td><td><p class="text-align-right">29</p></td><td><p class="text-align-right">94</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;Asia Pacific (n=146)</th><td><p class="text-align-right">6</p></td><td><p class="text-align-right">&nbsp;</p></td><td><p class="text-align-right">4</p></td><td><p class="text-align-right">12</p></td><td><p class="text-align-right">84</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;&lt;22.5 (n=212)</th><td><p class="text-align-right">9</p></td><td><p class="text-align-right">9</p></td><td><p class="text-align-right">8</p></td><td><p class="text-align-right">18</p></td><td><p class="text-align-right">86</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;22.5 to 24.9 (n=194)</th><td><p class="text-align-right">13</p></td><td><p class="text-align-right">13</p></td><td><p class="text-align-right">12</p></td><td><p class="text-align-right">39</p></td><td><p class="text-align-right">90</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;24.9 to 27.9 (n=222)</th><td><p class="text-align-right">11</p></td><td><p class="text-align-right">17</p></td><td><p class="text-align-right">11</p></td><td><p class="text-align-right">28</p></td><td><p class="text-align-right">88</p></td></tr><tr><th scope="row">&nbsp;&nbsp;&nbsp;&nbsp;&gt;27.9 (n=268)</th><td><p class="text-align-right">15</p></td><td><p class="text-align-right">16</p></td><td><p class="text-align-right">13</p></td><td><p class="text-align-right">36</p></td><td><p class="text-align-right">91</p></td></tr></tbody></table></div><p><small>Source: Adapted from FDA Review</small><br><small>Abbreviations: AD, Alzheimer’s Disease; ARIA-E, amyloid-related imaging abnormalities with edema; ARIA-H, amyloid-related imaging abnormalities with hemosiderin deposition; BMI, body mass index; MCI, mild cognitive impairment; TEAE, treatment-emergent adverse event</small></p><p>
		</p></div>
	</div>
</div><p></p></div><h2>GLOSSARY</h2><p><strong>CLINICAL TRIAL:</strong> Voluntary research studies conducted in people and designed to answer specific questions about the safety or effectiveness of drugs, vaccines, other therapies, or new ways of using existing treatments.<br><strong>COMPARATOR:</strong> A previously available treatment or placebo that is compared to the actual drug being tested.<br><strong>EFFICACY: </strong>How well the drug achieves the desired response when it is taken as described in a controlled clinical setting, such as during a clinical trial.<br><strong>PLACEBO: </strong>An inactive substance or “sugar pill” that looks the same as, and is given the same way as, an active drug or treatment being tested. The effects of the active drug or treatment are compared to the effects of the placebo.<br><strong>SUBGROUP: </strong>A subset of the population studied in a clinical trial. Demographic subsets include sex, race, and age groups.</p><p><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761269Orig1s001lbl.pdf"><strong>DRUG PACKAGE INSERT</strong></a></p><p class="text-align-right"><a class="btn btn-default" href="/drugs/drug-approvals-and-databases/drug-trials-snapshots"><span>Back to Drug Trials Snapshots</span></a></p>

<!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET-->
<!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET-->



              
                                            
              
            </div>

                                                  
                          <aside class="col-md-2" role="complementary">
                <section id="block-entityviewcontent-4" data-block-plugin-id="entity_view:node" class="block block-ctools block-entity-viewnode clearfix">
  
    

      

<div class="region region-">
  <aside class="lcds-card lcds-card--border-top">
    <ul role="menu" class="lcds-description-list">
      
                            


























  <li role="menuitem" class="node-current-date lcds-description-list__item">
    <div>
      <h2 class="lcds-description-list__item-heading">Content current as of:</h2>
      <p class="lcds-description-list__item-text"><time datetime="2024-10-08T00:00:00Z">10/08/2024</time>
</p>
    </div>
  </li>
              
              
<li role="menuitem" class="lcds-description-list__item">  
	<div>
		 
			     
						       

			  
						  

			  
						 
	</div>
</li>   

    </ul>

  </aside>
</div>


  </section>


              </aside>
            
                 </article>        
      </main>

    </div>  </div>
<div id="fda-survey-comments"></div>
<script src=https://touchpoints.app.cloud.gov/touchpoints/0eb673d9.js async></script>
<button class="btn btn-primary btn-vertical" id="survey-btn">Feedback</button>
<script src=https://touchpoints.app.cloud.gov/touchpoints/d45bb814.js async=""></script>
                <div class="region region-subscribe">
    <section id="block-entityviewcontent-5" data-block-plugin-id="entity_view:node" class="block block-ctools block-entity-viewnode clearfix">
  
    

      

  </section>


  </div>

  
      <footer id="footer" class="lcds-footer container-fluid">
        
    <div class="row lcds-footer__primary">
    <nav class="text-center">
      <div class="col-sm-4">
        <ul class="nav">
          <li><a href="/about-fda/about-website/fdagov-archive" >FDA Archive</a></li>
          <li><a href="/about-fda" >About FDA</a></li>
          <li><a href="/about-fda/about-website/internet-accessibility" >Accessibility</a></li>
        </ul>
      </div>
      <div class="col-sm-4">
        <ul class="nav">
          <li><a href="/about-fda/visitor-information" >Visitor Information</a> </li>
          <li><a href="/about-fda/about-website/website-policies" >Website Policies / Privacy</a></li>
          <li><a href="/about-fda/jobs-and-training-fda/no-fear-act" >No FEAR Act</a></li>
          <li><a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" >Vulnerability Disclosure Policy</a></li>
        </ul>
      </div>
      <div class="col-sm-4">
        <ul class="nav">
          <li><a href="/regulatory-information/freedom-information" title="Freedom of Information Act">FOIA</a></li>
          <li><a href="https://www.hhs.gov/" title="Health and Human Services" target="_blank">HHS.gov</a></li>
          <li><a href="https://www.usa.gov/" target="_blank">USA.gov</a></li>
        </ul>
      </div>
    </nav>
  </div>
    <div class="row lcds-footer__secondary">
    <div class="col-sm-12 col-md-6 col-lg-4 lcds-footer__social-links">
      <a href="/about-fda/contact-fda" class="btn btn-default btn-md">Contact FDA</a>
      <a href="https://www.facebook.com/FDA" title="Follow FDA on Facebook" class="no-disclaimer"> 
        <span class="fa fa-facebook fa-2x" aria-hidden="true">
          <span class="sr-only">Follow FDA on Facebook</span> 
        </span>
      </a>
      <a href="https://x.com/US_FDA" title="Follow FDA on X" class="no-disclaimer">
        <svg class="icon-svg-inline fa-2x" aria-hidden="true">
          <use href="/themes/custom/preview/assets/images/fa-icons.svg#icon-x-twitter">
        </svg>
        <span class="sr-only">Follow FDA on X</span>
      </a>
      <a href="https://instagram.com/FDA" title="Follow FDA on Instagram" class="no-disclaimer">
        <span class="fa fa-instagram fa-2x" aria-hidden="true"> 
          <span class="sr-only">Follow FDA on Instagram</span>
        </span>
      </a>
      <br class='visible-xs-inline'/>
      <a href="https://www.linkedin.com/company/fda/" title="Follow FDA on LinkedIn" class="no-disclaimer">
        <span class="fa fa-linkedin fa-2x" aria-hidden="true"> 
          <span class="sr-only">Follow FDA on LinkedIn</span>
        </span>
      </a>
      <a href="https://youtube.com/@US_FDA" title="View FDA videos on YouTube" class="no-disclaimer">
        <span class="fa fa-youtube fa-2x" aria-hidden="true"> 
          <span class="sr-only">View FDA videos on YouTube</span>
        </span>
      </a>
      <a href="/about-fda/contact-fda/subscribe-podcasts-and-news-feeds" title="Subscribe to FDA RSS feeds">
        <span class="fa fa-rss fa-2x" aria-hidden="true">
          <span class="sr-only">Subscribe to FDA RSS feeds</span>
        </span>
      </a>
    </div>
    <a href="/" title="FDA Homepage">
        <div class="visible-lg-block col-lg-4 text-center">
          <img src="/themes/custom/preview/assets/images/FDA_Logo_Icon_White.svg" height="60px" alt="Food and Drug Administration Logo">
        </div>
    </a>
    <div class="col-sm-12 col-md-6 col-lg-4 text-center lcds-footer__contact-number">
      <span class="fa fa-phone" aria-hidden="true"> </span> 
     <span class="sr-only">Contact Number</span>
      1-888-INFO-FDA (1-888-463-6332)
    </div>
  </div>
  
      <!--END WEBSITE FEEDBACK SNIPPET-->
  

    </footer>
    <a href="" id="btn-top" class="btn btn-primary btn-top"><span class="sr-only">Back to </span>Top</a>
  

  </div>

    
    <script type="application/json" data-drupal-selector="drupal-settings-json">{"path":{"baseUrl":"\/","pathPrefix":"","currentPath":"node\/423582","currentPathIsAdmin":false,"isFront":false,"currentLanguage":"en"},"pluralDelimiter":"\u0003","suppressDeprecationErrors":true,"fda_ckeditor_enhancements":{"basePath":"modules\/custom\/fda_ckeditor_enhancements"},"google_analytics":{"account":"G-273DTKB5QW","trackOutbound":true,"trackMailto":true,"trackTel":true,"trackDownload":true,"trackDownloadExtensions":"7z|aac|arc|arj|asf|asx|avi|bin|csv|doc(x|m)?|dot(x|m)?|exe|flv|gif|gz|gzip|hqx|jar|jpe?g|js|mp(2|3|4|e?g)|mov(ie)?|msi|msp|pdf|phps|png|ppt(x|m)?|pot(x|m)?|pps(x|m)?|ppam|sld(x|m)?|thmx|qtm?|ra(m|r)?|sea|sit|tar|tgz|torrent|txt|wav|wma|wmv|wpd|xls(x|m|b)?|xlt(x|m)|xlam|xml|z|zip"},"bootstrap":{"forms_has_error_value_toggle":1,"modal_animation":1,"modal_backdrop":"true","modal_focus_input":1,"modal_keyboard":1,"modal_select_text":1,"modal_show":1,"modal_size":"","popover_enabled":1,"popover_animation":1,"popover_auto_close":1,"popover_container":"body","popover_content":"","popover_delay":"0","popover_html":0,"popover_placement":"right","popover_selector":"","popover_title":"","popover_trigger":"click"},"ajax":[],"user":{"uid":0,"permissionsHash":"1b1b521ce0efd787b9481ef00f514b542eb396217a4d74c357d2ecd6b6b52a2d"}}</script>
<script src="/files/js/js_xP2P-a2AfusuVTFqrD8uHKMSZ46FoZMpbkc6_ORS8xM.js?scope=footer&amp;delta=0&amp;language=en&amp;theme=preview&amp;include=eJxdjtEKwjAMRX9oo74I_k3J0hiLXROSMJlfL1Ms4uM9JOdeFuFGGTq0PSp64j8wqdFW6ZG4yQJtdrSq4dMiEh4GmlRUNrLpWiDjnUoNsUz9Bh1ppR6eAFGsVOk5hA-738QCpdDnSVZt9ThPR5Pn8-nyA8cCNHjuxDxAAX1Lvnlo59H4Ai47WJ8"></script>

  <script type="text/javascript"  src="/VSlrlmgubQttxfPEfQ/Li7tkShpS4p6Vp/ahssI1QC/NQ/0mZGl5fUAB"></script></body>
</html>
